FDA Investigator Christina N Maurino

Christina N Maurino has conducted inspections on 109 sites in 5 countries as of 28 May 2015. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
109
Last Inspection Date:
28 May 2015
Investigator Role:
FDA Investigator
Redica ID:
100007236
Countries of Inspections:
United States of America, Romania, Ireland, Germany, France
FDA Investigators that have inspected at least one site in common with Christina N Maurino:
Alberto A Viciedo, Allen Lou, Amy A Johnson, Amy Kim, Amy L Singer, Amy Wyan Mai, Ana S Cabrera, Anastasia I Offordile, Andrew F Cohen, Angela Shepas, Anthony E Keller, RPh, Anthony M Criscuolo, Jr, Anthony N Onianwa, Barbara J Maulfair, Byungja E Marciante, Cary Greene, Charles I Ann, Charles J Chacko, Cheryl A Grandinetti, Cheryl J Legrand, Christine M Cerenzio, Craig W Swanson, Daniel J Grabicki, David H Smith, Dawn L Wydner, Deborah B Nixon, Denise M Visco, Investigator, Diane M Gubernot, Dorothy J Denes, Douglas C Kovacs, Dung N Tran, Edward O'shaughnessy, Emest F Bizjak, Emily A Walters, Emmanuel Jramos Maldonado, Eric Rothschild, Erin D Mccaffery, Esteban Beltran, Frank J Marciniak, George Pyramides, Gianine E Delade, Gianine E Tompkins, Gobiga Vanniyasingam, Guerlain Ulysse, Gwyn G Dickinson, Helen B Ricalde, Helen Verdel, Hugh M Mcclure, II, Jason M Sluzynski, Jean M Kelahan, Jeffrey J Ebersole, Jennifer A Bazergui, Jennifer L Custodio, Jennifer Macmillan, Jessica M Monteiro, Joan A Loreng, Jogy George, Jonee J Mearns, Jose M Cayuela, Joseph F Mcginnis, RPh, Justin H Price, Justine Tomasso, Karen E D'orazio, Kassa Ayalew, MD, Kathleen B Swat, Keith M Reilly, Kelli F Dobilas, Kelly Doremus, Kelly I Anderson, Kerry A Kurdilla, Kinh Q Mac, Kip J Hanks, Kristina L Conroy, Kristy A Zielny, Krystal O Ogunremi, Laishan L Lam, Lata C Mathew, PhD, Lauren Iacono Connors, PhD, Lawrence R Johnson, Li Li, Liatte Kreuger, PharmD, Lisa Harlan, Lisa Mathew, LT Colin E Tack, BSE, Marcelo O Mangalindan, Jr, Margaret M Sands, Marjorie D Schultz, Matthew A Spataro, Mayar M Mussa, Melissa B Libby, Melissa T Roy, Michael R Klapal, Michael Serrano, Monika Borkowska, Myoshi M Francis, Nancy F Scheraga, Nerizza B Guerin, Nilufer M Tampal, PhD, Nina Yang, Paul L Bellamy, Perez, Peter R Lenahan, Regina T Brown, Remache, Richard D Manney, Robert G Ruff, Robert Jennings, Rodney T Allnutt, Rodrigo Vilchez, Roger J Adams, Russell J Glapion, Saleem A Akhtar, Sarah Forney, Schultz, Sherri J Liu, Shirley H Isbill, Sinai I Davis, Stephanie T Durso, Stephen J Mottola, Susan M Halsted, Tania E Garcia, Tania E Vizcaino, Tara G Bizjak, Tara R Gooen, Thomas N Adjabeng, Tonia F Bernard, Tyanna N Hadley, Valerie C Reed, Yasmin B Rios, Yvesna C Blaise, Zakaria I Ganiyu

Christina N Maurino's Documents

Publish Date Document Type Title
December, 2012 FDA 483 NPS Pharmaceuticals, Inc. - Form 483, 2012-12-04
December, 2010 EIR Concordia Clinical Research (IRB) - EIR, 2010-12-30
February, 2012 FDA 483 Merck & Co., Inc. - Form 483, 2012-02-29
July, 2013 FDA 483 Bayer HealthCare Pharmaceuticals Inc. - Form 483, 2013-07-11
February, 2015 EIR Nelson Laboratories Fairfield Inc. - EIR, 2015-02-03
December, 2014 EIR BioClinica Inc. - EIR, 2014-12-10
February, 2012 EIR Merck & Co., Inc. - EIR, 2012-02-29
December, 2010 FDA 483 Response Concordia Clinical Research (IRB) - Form 483R, 2011-01-13
January, 2012 EIR Hackensack University Medical Center - EIR, 2012-01-24
July, 2013 EIR Bayer HealthCare Pharmaceuticals Inc. - EIR, 2013-07-11
February, 2013 FDA 483 Forest Research Institute, Inc. - Form 483, 2013-02-21
December, 2010 FDA 483 Concordia Clinical Research (IRB) - Form 483, 2010-12-30
March, 2013 EIR Perceptive Informatics, Inc. - EIR, 2013-03-28
January, 2015 EIR Canfield Scientific, Inc. - EIR, 2015-01-22
January, 2010 EIR Celularity, Inc. dba LifebankUSA - EIR, 2010-01-20
February, 2013 EIR Forest Research Institute, Inc. - EIR, 2013-02-21
January, 2015 FDA 483 Canfield Scientific, Inc. - Form 483, 2015-01-22
March, 2013 FDA 483 Prof. Dr. Martin Schuler - Form 483, 2013-03-22
August, 2014 FDA 483 Novartis Pharmaceuticals Corporation - Form 483, 2014-08-05
October, 2012 FDA 483 Richard A. D'Amico, MD, FACS - Form 483, 2012-10-11
January, 2012 FDA 483 Hackensack University Medical Center - Form 483, 2012-01-24

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more